01 Industry overview
The dme industry at a glance
The global durable medical equipment market was valued at $266.5 billion in 2025 and is expanding as aging populations, chronic disease and home-based care increase equipment demand.
- $266.5B[39]
- Global market size, 2025
- 6.2%[39]
- Forecast CAGR, 2026–2035
- 329,700[55]
- U.S. manufacturing jobs, 2025
- 37.0%[39]
- North America share, 2025
- Market size
- The global durable medical equipment market was valued at $266.50 billion in 2025. U.S. retail spending on durable medical equipment reached $86.4 billion in 2024, up 5.4% year over year.[39][14]
- Forecast & CAGR
- Global DME revenue is projected to reach $486.34 billion by 2035, representing a 6.2% compound annual growth rate from 2026 to 2035. Asia Pacific is forecast to grow at 7.6% annually over the same period, faster than North America at 6.1%.[39]
- Market share & regions
- North America held 37.0% of the global market in 2025, while Asia Pacific generated $74.62 billion and is forecast to grow at 7.6% annually through 2035. Europe is projected to reach $109.89 billion by 2035.[39]
- Segmentation
- Monitoring and therapeutic devices accounted for 89.5% of global revenue in 2025, according to Grand View Research. By end use, hospitals represented 34.1% of revenue, while Global Market Insights estimates home healthcare will reach a 41.6% share by 2035.[21][39]
- Key players & concentration
- The market remains fragmented: Global Market Insights identifies Medline Industries as the leader with more than 3.5% share in 2025, while its five named leading companies collectively held 10.5%. Named participants include Medline Industries, Drive DeVilbiss Healthcare, Invacare, ResMed and Philips Respironics.[39]
- Pricing
- In the U.S. Medicare market, most DMEPOS products are reimbursed under fee-schedule amounts, with payment generally limited to the lesser of the supplier’s actual charge or the applicable fee schedule. For newly covered items without an established fee, CMS uses comparable-item fees or supplier and retail price lists through gap-filling.[14]
- Trends, drivers & challenges
- Demand is being supported by aging populations, chronic disease management and the shift toward home-based care; home healthcare DME is forecast to grow at 7.2% annually from 2026 to 2035. Constraints include payer scrutiny, competitive bidding, reimbursement limits and the administrative burden of accreditation, documentation and fulfillment.[39][14]
- Consumer behavior & competition
- Home healthcare is becoming a major demand channel: the segment is projected to hold 41.6% of global DME revenue by 2035. In the U.S., 28.4 million Original Medicare beneficiaries used physician/DME services in 2024, while private insurance and out-of-pocket channels are important for premium mobility, monitoring and respiratory products.[39][56]
- M&A
- Private-equity activity remained visible in 2026: AIP LLC announced an approximately $1.2 billion acquisition of Avanos Medical, and Palladium Equity Partners established a platform with DME Express. Quipt Home Medical also acquired Ballad Health DME locations serving more than 12,500 patients.[22]
- Regulation
- Medicare DMEPOS payment is governed by statutory fee-schedule rules, including ceiling and floor limits for different categories. CMS establishes new fee amounts under 42 CFR §414.238 when no Medicare fee exists, using comparable equipment or supplier and retail price data.[14]
- Latest news
- The latest identified DME-sector transaction activity includes AIP LLC’s approximately $1.2 billion acquisition of Avanos Medical in April 2026 and Palladium Equity Partners’ creation of a hospice-focused DME platform with DME Express. These deals indicate continued strategic and private-equity interest in chronic-care, respiratory and home-based equipment.[22]
02 Ranking
Top 10 Companies in the Dme Industry
The leading companies in the dme industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 11, 2026 · Next review December 11, 2026
Medline leads Gitnux's 2026 dme ranking with an Overall score of 9.9, with revenue growth 11.5% backed by healthcare manufacturing across home care points. ResMed is the highest-ranked connected medical device manufacturer at 9.4, driven by 10% revenue growth and R&D at 6.7% of revenue.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in medical-surgical & home care
Medline
US
Ranked #1 · 9.9 · Medical-surgical & home care
Why we picked it: Its medical-surgical and home-care equipment serves home care, supported by 11.5% revenue growth.
Leader in sleep & respiratory devices
ResMed
US
Ranked #2 · 9.4 · Sleep & respiratory devices
Why we picked it: It sells connected sleep-apnea and respiratory devices, with 10% growth and 6.7% R&D intensity.
Leader in patient handling & beds
Stryker
US
Ranked #3 · 9.2 · Patient handling & beds
Why we picked it: Its patient handling and intensive-care equipment spans care settings, supported by 19.5% operating margin.
Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.
Full ranking
| # | Company | Overall ↓ | Impact | Company snapshot |
|---|---|---|---|---|
| 1 | Medline Medical-surgical & home care · US | 9.9 | 9.9 | |
Company snapshot · Medline · Data as of November 11, 2026 Medline manufactures healthcare products and serves all points of care, including home care.[57]
| ||||
| 2 | ResMed Sleep & respiratory devices · US | 9.4 | 9.1 | |
Company snapshot · ResMed · Data as of November 11, 2026 ResMed is a global leader in connected medical devices for sleep and respiratory care.[20]
| ||||
| 3 | Stryker Patient handling & beds · US | 9.2 | 8.4 | |
Company snapshot · Stryker · Data as of November 11, 2026 Stryker supplies patient handling, emergency and intensive-care equipment used across care settings.[58]
| ||||
| 4 | Pride Mobility Products Power mobility products · US | 8.6 | 9.0 | |
Company snapshot · Pride Mobility Products · Data as of November 11, 2026 Pride designs and manufactures power wheelchairs, mobility scooters and lift recliners.[59]
| ||||
| 5 | Sunrise Medical Manual & power mobility · DE | 8.6 | 8.8 | |
Company snapshot · Sunrise Medical · Data as of November 11, 2026 Sunrise Medical develops and manufactures assistive mobility devices distributed in more than 130 countries.[60]
| ||||
| 6 | Arjo Patient handling, beds and mobility equipment, global · SE | 8.4 | 8.2 | |
Company snapshot · Arjo · Data as of November 11, 2026 Arjo supplies patient handling systems, medical beds and mobility products across more than 100 countries.[61]
| ||||
| 7 | Permobil Complex rehabilitation and assistive mobility equipment · SE | 8.2 | 7.8 | |
Company snapshot · Permobil · Data as of November 11, 2026 Permobil develops assistive technology and complex rehabilitation solutions for people with disabilities.[62]
| ||||
| 8 | Lincare Respiratory homecare and DME, US · US | 8.2 | 7.7 | |
Company snapshot · Lincare · Data as of November 11, 2026 Lincare is a leading US respiratory homecare provider serving approximately 1.8 million patients.[63]
| ||||
| 9 | Ottobock Prosthetics, orthotics and mobility equipment · DE | 8.2 | 7.7 | |
Company snapshot · Ottobock · Data as of November 11, 2026 Ottobock develops prosthetic, orthotic and mobility solutions for people with disabilities.[21]
| ||||
| 10 | Apria Home respiratory and medical equipment, US · US | 8.2 | 7.7 | |
Company snapshot · Apria · Data as of November 11, 2026 Apria provides home respiratory therapy, sleep therapy and home medical equipment in the United States.[64]
| ||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 11, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Julian Richter. (2026, February 13). Top 10 companies in the dme industry. In Dme Industry Statistics. Gitnux. https://gitnux.org/dme-industry-statistics/#top-companies
03 Trends & forecasts
Top 10 Dme Industry Trends & Forecasts 2027
What is changing in the dme industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Home care outpaces institutional demand
High confidenceU.S. durable medical equipment retail spending reached $86.4 billion in 2024, up 5.4% year over year. Medicare limits DME coverage largely to medically necessary items used in a patient’s home, reinforcing home-based delivery and servicing models.[14]
Forecast 2027: In 2027, home care should remain the fastest-growing major DME channel, supported by hospital-at-home programs, aging in place and demand for respiratory, mobility and monitoring equipment. Suppliers with installation, training and recurring-service capabilities are likely to outperform product-only distributors.
02Aging populations expand mobility demand
High confidenceThe U.S. population aged 65 and older reached 58 million in 2022, up 34% from 2012, and is projected to represent one in five Americans by 2030. AARP also reports that aging in place is a continuing preference among older adults.[65]
Forecast 2027: By 2027, demand should rise particularly for wheelchairs, walkers, beds, transfer equipment, bathroom safety products and home monitoring. Growth will be strongest in regions where the older population is expanding rapidly and caregiver availability is constrained.
03Chronic disease sustains respiratory demand
High confidenceThe World Health Organization reported that noncommunicable diseases caused at least 43 million deaths in 2021, including 4 million from chronic respiratory diseases and more than 2 million from diabetes-related causes. These conditions require long-term monitoring, oxygen therapy, ventilation and related supplies.[66]
Forecast 2027: In 2027, chronic respiratory and metabolic conditions should continue generating recurring DME utilization rather than one-time purchases. Respiratory equipment, glucose-monitoring products and consumable accessories are likely to grow faster than general-purpose equipment.
04Connected monitoring becomes standard
High confidenceFDA guidance treats internet-connected medical devices as cyber devices when they contain software, can connect to the internet and may be vulnerable to cyber threats. The requirements include vulnerability-management plans, postmarket updates and software bills of materials for applicable submissions.[67]
Forecast 2027: By 2027, connected monitoring should expand across sleep, respiratory, cardiac, glucose and mobility applications. Suppliers will increasingly compete on data integration, remote support and adherence management rather than on hardware alone.
05Cybersecurity costs rise for connected DME
High confidenceThe FDA issued a January 2025 safety communication describing vulnerabilities in certain patient monitors that could permit unauthorized control and exfiltration of patient data after internet connection. FDA guidance also recommends lifecycle vulnerability management, patching and third-party software assessments.[67]
Forecast 2027: In 2027, cybersecurity compliance, patch support and incident response will become more visible costs in DME procurement. Connected-device vendors that cannot demonstrate updateability and secure software inventories may lose hospital, payer and home-care contracts.
06Reimbursement remains fee-schedule constrained
High confidenceCMS states that most DMEPOS products are paid under fee-schedule rules and that Medicare pays 80% of the supplier’s actual charge or the fee-schedule amount, whichever is lower. CMS publishes fee schedules with payment amounts, floors and ceilings, including quarterly 2026 files.[14]
Forecast 2027: In 2027, reimbursement discipline should keep pricing growth below underlying demand growth for many standardized products. Suppliers will need higher delivery density, inventory productivity and recurring revenue to protect margins.
07Prior authorization broadens administrative load
High confidenceCMS added 20 HCPCS codes to its DMEPOS master list effective October 28, 2026. The agency also began or scheduled nationwide prior-authorization requirements for selected orthoses, pressure-reducing support surfaces and a manual wheelchair base, with additional phases extending into 2027.[14]
Forecast 2027: In 2027, documentation, clinical-order coordination and authorization turnaround will become more important competitive differentiators. Smaller suppliers may outsource compliance or narrow product coverage if administrative costs rise faster than reimbursement.
08Competitive bidding remains a policy overhang
Medium confidenceCMS describes a temporary gap in the DMEPOS Competitive Bidding Program beginning January 1, 2024, while continuing claims-based monitoring of access and health outcomes for affected product categories and regions.[14]
Forecast 2027: During 2027, suppliers should continue planning for possible competitive-bidding expansion or redesigned contract models. Any restart would favor scale, geographic coverage, lower operating costs and strong beneficiary-access evidence.
09Improper-payment scrutiny intensifies
High confidenceCMS reported an estimated $2.3 billion in DMEPOS improper payments for 2025, equal to a 24.1% improper-payment rate. Urological supplies represented approximately $885 million of projected improper payments, with documentation deficiencies a major source of errors.[14]
Forecast 2027: In 2027, suppliers should face more prepayment review, targeted audits, beneficiary outreach and data-driven fraud controls. Compliance technology and complete clinical documentation will increasingly affect cash flow and payer relationships.
10Recurring rental models gain share
Medium confidenceCMS’s DME methodology separates rental indicators and provides utilization, allowed-amount and Medicare-payment data for DMEPOS claims. Viemed reported that rental and sale of home medical equipment represented 90.8% of its 2025 revenue, illustrating the importance of recurring home-equipment economics.[56][18]
Forecast 2027: By 2027, rental, maintenance and resupply revenue should become more central to supplier strategies, especially in respiratory and complex-care categories. Providers will favor models that improve adherence and reduce avoidable hospital utilization over simple equipment delivery.
04 Statistics
Technology & Innovation
AI and digital work sits on a measured baseline: 89% of medtech/IVD professionals planned AI or digital solutions in 2020, with cloud adoption and analytics framed across manufacturing and postmarket needs.
Digital Transformation in the medical devices sector (sector benchmark)
- Across medtech and IVD professionals worldwide, 89% said their company had implemented or planned to implement AI or digital solutions in its product range in 2020.[1]
- Across medtech and IVD professionals worldwide, 87% said their company had implemented or planned to implement AI or digital solutions in regulatory or quality-management systems in 2020.[1]
- Across medtech manufacturing executives, 64% highly prioritized digitizing manufacturing in a 2022 survey.[2]
- Across medtech companies, 35% created value but failed to meet all digital-transformation targets in 2021.[3]
- Across medtech companies, 36% achieved limited value and no sustainable change from digital transformation in 2021.[3]
- Across medtech companies, 29% met or exceeded their digital-transformation targets with sustainable change in 2021, according to BCG’s global survey.[3]
Technology Adoption in the medical devices sector (sector benchmark)
- Across healthcare industrial-ecosystem SMEs in Europe, 17.3% already used robotics in 2023.[4]
- Across healthcare industrial-ecosystem SMEs in Europe, 8.6% already used remote patient-monitoring technologies in 2023.[4]
- Across healthcare industrial-ecosystem SMEs in Europe, 31.0% already used cloud technologies in 2023.[4]
- Among emerging medtech companies, 38% had adopted clinical-trial-management systems, compared with 72% of enterprise and global companies in the 2025 benchmark.[5]
- Among emerging medtech companies, 62% had adopted electronic trial-master-file systems, compared with 89% of enterprise and global companies in the 2025 benchmark.[5]
- Across healthcare industrial-ecosystem SMEs in Europe, 13.7% already used artificial intelligence in 2023.[4]
Cloud Computing in the medical devices sector (sector benchmark)
- Across surveyed medtech organizations, 31% managed all postmarket-surveillance processes with cloud-based technology in 2025.[5]
- Across surveyed medtech organizations, 33% reported reliable enterprise-wide use of cloud-based technologies in 2025.[5]
- Across medical-device manufacturing respondents in the global Industry Cloud Study, 66% reported that 50%–74% of infrastructure was in the cloud in 2022.[6]
- Across medical-device manufacturing respondents in the global Industry Cloud Study, 21% reported that 75%–100% of infrastructure was in the cloud in 2022.[6]
Big Data in the medical devices sector (sector benchmark)
- 66.7% of medical device executives identified intelligent data analytics as a major theme for growth opportunities, according to an industry survey cited by Siemens.[7]
- Across medtech companies surveyed by Model N, nearly 70% already used or planned to use data and analytics in 2023.[8]
- 49% of medtech companies reported struggling with untimely data in Model N’s 2025 survey of industry leaders.[8]
- Across healthcare industrial-ecosystem SMEs in Europe, 15.3% had adopted big data and related data analytics in 2023.[4]
- 45% was the average share of planned digital-enabler spending that medtech companies allocated to infrastructure, cloud enablement, architecture modernization, and AI and big data, globally, in 2021.[3]
- Across medtech and biopharma companies surveyed in 2018, 67% of medtech firms invested in data analytics for reporting.[9]
IoT in the medical devices sector (sector benchmark)
- Among European healthcare industrial-ecosystem SMEs already using IoT, 21.4% used predictive maintenance for production assets in 2023.[4]
- Among European healthcare industrial-ecosystem SMEs already using IoT, 22.3% used energy-saving devices such as smart lighting, HVAC or elevators in 2023.[4]
- Among healthcare and medical-device IoT respondents, 84% planned to increase their connected-device estate in 2023.[10]
- Across healthcare industrial-ecosystem SMEs in Europe, 20.4% already used Internet of Things technologies in 2023.[4]
- Among healthcare and medical-device IoT respondents, 9% had deployed between 10,001 and 100,000 connected devices in 2023.[11]
- Among healthcare and medical-device IoT respondents, 31% planned to double the number of connected devices deployed in 2023.[10]
05 Statistics
Data & Analytics
We focus on connected-device signal counts and quality controls, including 237 classifiable U.S. FDA 510(k) clearances for cloud-connected devices in 2025 and a 24.1% CMS improper-payment rate in 2025.
Business intelligence in the dme industry
- 3,225 U.S. FDA 510(k) clearances were recorded in the connected-care dataset in 2025.[12]
- 3,129 U.S. FDA 510(k) clearances were recorded in the connected-care dataset in 2024.[12]
- 580 classifiable U.S. FDA 510(k) clearances described digitally connected devices in 2025.[12]
- 47 million annual patient encounters were supported by HCA Healthcare’s integrated technology platforms and advanced analytics in 2025.[13]
- 237 classifiable U.S. FDA 510(k) clearances described cloud-connected devices in 2025.[12]
Data analytics in the dme industry
- 135 classifiable U.S. FDA 510(k) clearances described cloud-connected devices through July 26, 2026.[12]
- 74.1% was the 2025 improper-payment rate for U.S. urological supplies under DMEPOS.[14]
- $2.3 billion in U.S. DMEPOS improper payments were identified by CMS in 2025.[14]
- 24.1% was the U.S. DMEPOS improper-payment rate identified by CMS in 2025.[14]
- 17.3% of classifiable U.S. FDA 510(k) clearances described digitally connected devices in 2024.[12]
- 19.8% of classifiable U.S. FDA 510(k) clearances described digitally connected devices through July 26, 2026.[12]
Data Quality in the medical devices sector (sector benchmark)
- 45.9% of healthcare-sector business partners identified data quality as a major challenge in managing digital product information in the 2021 survey.[15]
- 56% of medical-device companies used non-validated general-purpose tools for clinical data collection in the 2024 MedTech industry survey.[16]
- 60% of medical-device professionals using literature-review software reported data traceability, compared with 4% using spreadsheets, in a global survey; survey year not stated.[17]
- 73% of medical-device professionals using literature-review software trusted their data quality, compared with 38% using spreadsheets, in a global survey; survey year not stated.[17]
- 51% of medical-device companies still managed postmarket-surveillance processes and data manually or partially manually in the 2025 benchmark survey.[5]
Data Governance in the medical devices sector (sector benchmark)
- 31.4% of healthcare-sector business partners had a digital-asset-management system for storing images and product data sheets in the 2021 survey.[15]
- More than 72% of healthcare-sector business partners had not established a product-master-data system reflecting data governance in the 2021 survey.[15]
- More than 30% of healthcare-sector business partners had no clear formal data-governance guidelines in the 2021 survey.[15]
- 62.3% of healthcare-sector business partners identified creating a central data master as a single source of truth as the greatest digital-product-information challenge in 2021.[15]
KPIs in the dme industry
- 21,800 patients was Lincare’s 2024 service-volume KPI for ventilator treatment.[18]
- 5 calendar days was the CMS notification KPI for suppliers unable to provide prescribed DMEPOS equipment or services.[14]
- 385,000 oxygen patients was Lincare’s 2024 service-volume KPI for oxygen care.[18]
- 20 U.S. DMEPOS product-category utilization files were listed by CMS for monitoring through June 2024.[14]
- 4.8 million patients was AdaptHealth’s annual patient-volume KPI in 2026.[19]
- 24.1% was the CMS-measured U.S. DMEPOS improper-payment rate in 2025, a core compliance KPI for suppliers.[14]
06 Statistics
Strategy & Growth
We treat growth as a market-structure issue and a scale issue, with the global DME market projected to be $260.8 billion in 2026 and consolidation indicated by a 36% decline in U.S. DME locations between 2013 and 2025.
Growth in the dme industry
- 10% was ResMed’s fiscal-2025 year-over-year net-revenue growth on a constant-currency basis.[20]
- 5.5% is the projected compound annual growth rate for the global durable medical-equipment market from 2026 to 2033.[21]
- 36.3% was North America’s share of global durable medical-equipment market revenue in 2025.[21]
- 36% was the decline in the number of United States DME locations between 2013 and 2025.[22]
- $260.8 billion is the projected global durable medical-equipment market value for 2026.[21]
- $85 billion was the estimated United States durable medical-equipment market size in 2024.[22]
Differentiation in the dme industry
- 7% of Accendra Health’s fiscal-2025 revenue came from wound-care products and services.[18]
- 81% of Accendra Health’s fiscal-2025 revenue came from commercial payors, compared with 18% from Medicare fee-for-service and 1% from Medicaid.[18]
- 16% of Accendra Health’s fiscal-2025 revenue came from respiratory products and services.[18]
- 8% of Accendra Health’s fiscal-2025 revenue came from ostomy products and services.[18]
- 100,000-plus devices formed InfuSystem’s United States and Canadian medical-equipment fleet in 2025.[18]
- 4% of Accendra Health’s fiscal-2025 revenue came from urology products and services.[18]
Mergers and acquisitions in the dme industry
- 36% was the reduction in United States DME locations between 2013 and 2025, indicating consolidation and scale advantages.[22]
- 1,649 mergers and acquisitions worth $88 billion were announced in the durable medical and home-health equipment sector from the third quarter of 2020 through the second quarter of 2025.[23]
- 6 acquisitions, 27 openings and 107 clinic combinations, closures or sales were recorded by one medical-equipment provider during 2025.[24]
- 52 equipment transactions led the medical-technology M&A category in 2024 in one sector transaction review.[25]
- 83 medical-technology M&A transactions were announced in the first quarter of 2026, with medical equipment representing 31% of activity.[26]
- 1,237 buyouts worth $74 billion were announced in the durable medical and home-health equipment sector from the third quarter of 2020 through the second quarter of 2025.[23]
Strategic partnerships in the dme industry
- 746 unique DME items were ordered for 136 patients in a 2023 NYC Health + Hospitals DME-benefit pilot.[27]
- 262 California patients receiving DME supplies from Acelis identified a language other than English or Spanish in 2025.[28]
- 255 California patients receiving DME supplies from Acelis identified Spanish as a primary or threshold language in 2025.[28]
- 437 California patients were served by Acelis with durable medical equipment or ventricular-assist-device supplies in 2025.[28]
- 4 DME locations and more than 12,500 patients were included in Ballad Health DME’s reported acquisition profile in 2026.[22]
- More than 2,000 sites of care were served by InfuSystem through its hospital and payer relationships in 2025.[18]
07 Statistics
People & Workforce
We capture workforce and quality-management constraints that show up in operating execution, including hybrid roles at 40% of respondents and resistance to change cited as a quality-management challenge.
Remote Work in the medical devices sector (sector benchmark)
- Remote medical device and diagnostics professionals reported a median salary of $142,000 in 2023, according to an industry salary survey.[29]
- Remote medical device and diagnostics professionals reported a median 4% pay increase in 2023, according to an industry salary survey.[29]
- About 50% of medical device and diagnostics professionals worked fully remotely in 2023, based on 226 usable survey responses in the United States.[29]
- Remote medical device and diagnostics employees worked an average of 41.5 hours per week in 2023, compared with 43 hours for office-based employees.[29]
Hybrid Work in the medical devices sector (sector benchmark)
- Hybrid medical device and diagnostics professionals represented about 40% of respondents in MD+DI’s 2023 salary survey, covering 226 usable responses.[29]
- Hybrid medical device professionals reported a median salary of $150,000 in 2026, compared with $140,000 for remote and $116,000 for in-office professionals.[29]
- Hybrid medical device and diagnostics professionals reported a median salary of $135,000 in 2023, according to an industry salary survey.[29]
- Hybrid medical device and diagnostics professionals reported a median 4% pay increase in 2023, according to an industry salary survey.[29]
Employee Engagement in the medical devices sector (sector benchmark)
- In medical devices, 23% of employees disagreed that their total compensation was fair relative to similar roles at other companies in the 2026 benchmark.[30]
- In medical devices, 73% of employees were engaged in benchmark data collected from July 2025 through June 2026, predominantly across Northern America, Oceania, Europe and Asia.[30]
- In medical devices, 91% of employees agreed they understood how their work contributed to company goals in benchmark data collected through June 2026.[30]
- Medical devices organizations had a median employee net promoter score of 14 in Culture Amp’s 2026 benchmark.[30]
Change Management in the medical devices sector (sector benchmark)
- Among pre-market medical device companies surveyed in 2023, 25% cited resistance to change efforts as a quality-management challenge.[16]
- Among pre-market medical device companies surveyed in 2023, 18% cited lack of management buy-in as a challenge to improving quality management processes.[16]
- Among post-market medical device companies surveyed in 2023, 37% cited resistance to change efforts as a challenge to improving quality management processes.[16]
- Only 2% of surveyed medical device manufacturers rated their ability to estimate product-change costs as excellent, while 10% rated it poor.[31]
- Among post-market medical device companies surveyed in 2023, 23% cited lack of management buy-in as a challenge to improving quality management processes.[16]
08 Statistics
Customer & Sales
We track how purchase decisions form around evidence and trials, with 66% of U.S. healthcare buyers citing live demonstrations or product trials as the strongest driver in 2025.
Customer experience in the dme industry
- 35% of U.S. survey respondents said they were familiar with durable medical equipment in 2022.[32]
- 69% of U.S. respondents familiar with durable medical equipment rated delivery timeliness as a very positive experience in 2022.[32]
- 4% of U.S. respondents familiar with durable medical equipment preferred receiving it by mail in 2022.[32]
- 64% of U.S. respondents familiar with durable medical equipment rated driver or technician care as a very positive experience in 2022.[32]
- 65% of U.S. respondents familiar with durable medical equipment rated driver or technician knowledge as a very positive experience in 2022.[32]
Customer retention in the dme industry
- 65% of healthcare buyers surveyed in the United States said they evaluate new providers each time they consider a new home medical equipment solution in 2025.[33]
- 35% of healthcare buyers surveyed in the United States said they typically use the same provider when considering new home medical equipment solutions in 2025.[33]
Customer acquisition in the dme industry
- 66% of healthcare buyers surveyed in the United States said live demonstrations or product trials most strongly advance a home medical equipment purchase decision in 2025.[33]
- 72% of healthcare buyers surveyed in the United States said evidence of return on investment or cost savings most strongly advances a home medical equipment purchase decision in 2025.[33]
- 61% of healthcare buyers surveyed in the United States said customer case studies with outcomes data most strongly advance a home medical equipment purchase decision in 2025.[33]
09 Statistics
Marketing & Brand
We note that creator/influencer spend has tightened, with 8% of healthcare and pharmaceutical marketers reporting dedicated but shrinking budgets in 2026 and 10% reporting no investment.
Influencer Marketing in the medical devices sector (sector benchmark)
- 8.57 million influencer posts about the health industry were published globally in 2023, across the platforms measured by Sprout Social.[34]
- 1.07% was the average engagement rate for health-industry influencer posts globally in 2023, across the platforms measured by Sprout Social.[34]
- 8% of healthcare and pharmaceutical marketers had dedicated but shrinking budgets for creator or influencer marketing in 2026.[35]
- 10% of healthcare and pharmaceutical marketers reported that they did not invest in creator or influencer marketing in 2026.[35]
- 29% of healthcare and pharmaceutical marketers had dedicated but flat budgets for creator or influencer marketing in 2026.[35]
10 Statistics
Operations & Execution
We quantify operational pressure through depreciation, margins, and improper-payment projections, including AdaptHealth patient-equipment depreciation up 6.6% to $341.3 million in 2025.
Process optimization in the dme industry
- 6.6% was the increase in AdaptHealth’s patient-equipment depreciation expense in 2025, reaching $341.3 million in the United States.[18]
- 8.1% was AdaptHealth’s operating-income margin in 2024, before falling to 2.8% in 2025 in the United States.[18]
- 35% of total costs and expenses at AdaptHealth were attributable to cost of net revenue in 2025, based on reported costs of $2.636 billion and revenue of $3.245 billion in the United States.[18]
- 2.2% was the year-over-year increase in AdaptHealth’s total cost of net revenue in 2025, rising to $2.636 billion in the United States.[18]
- 2.1% was the year-over-year increase in AdaptHealth’s Sleep Health revenue in 2025, reaching $1.378 billion in the United States.[18]
Operational efficiency in the dme industry
- 325 operating locations supported Rotech Healthcare’s home-medical-equipment operations across 46 U.S. states in 2023.[36]
- 725.8 million dollars was Rotech Healthcare’s revenue in 2024, compared with $753.4 million in 2023 in the United States.[18]
- 6 core business lines were operated by Rotech Healthcare in 2024: oxygen, ventilators, sleep therapy, wound care, diabetes and DME in the United States.[18]
- 4,200 employees worked at Rotech Healthcare across its U.S. operations in 2023.[36]
- 28.4% was Rotech Healthcare’s gross margin in 2024, calculated from $364.661 million gross profit and $725.756 million revenue in the United States.[18]
Quality management in the dme industry
- 105 million dollars was the approximate projected amount of improper payments for wheelchair accessories in fiscal year 2024 in the United States.[14]
- 21.4% was CMS’s projected improper-payment rate for DMEPOS claims in fiscal year 2024 in the United States.[14]
- 1.9 billion dollars was CMS’s projected amount of DMEPOS improper payments in fiscal year 2024 in the United States.[14]
- 278 million dollars was CMS’s projected amount of improper payments for glucose monitors in fiscal year 2024 in the United States.[14]
- 255 million dollars was the approximate projected amount of improper payments for urological supplies in fiscal year 2024 in the United States.[14]
Supply chain in the dme industry
- 39.9% of AdaptHealth’s revenue was represented by product and supply costs in 2025 in the United States.[18]
- 5.4% of AdaptHealth’s revenue was represented by other operating expenses in 2025 in the United States.[18]
- 23.1% of AdaptHealth’s revenue was represented by salaries, labor and benefits in 2025 in the United States.[18]
- 361.095 million dollars was Rotech Healthcare’s total cost of revenues in 2024 in the United States.[18]
- 2.3% of AdaptHealth’s revenue was represented by rent and occupancy costs in 2025 in the United States.[18]
Outsourcing / Offshoring in the medical devices sector (sector benchmark)
- $18.5 billion was the European medtech CDMO market in 2023.[37]
- $26.3 billion was the U.S. medtech CDMO market in 2023, after 12.9% growth from 2022.[37]
- More than half of 59 global medtech CDMO transactions in 2023 had cross-border characteristics.[37]
- 335 U.S. medical device contract manufacturers were identified in 2022, up from 314 in the prior registry.[37]
- 11.4% was the year-over-year growth rate of the global medtech outsourcing market in 2023.[37]
11 Statistics
Finance & Pricing
We treat pricing risk as policy-driven: competitive bidding is linked to a 23% decline in Medicare DME prices in the U.S. in a 2026 study and a 24.1% CMS improper-payment rate in 2025.
Pricing strategy in the dme industry
- 154,000 suppliers was the approximate number of DME suppliers represented in the study’s Medicare supplier population in the United States.[38]
- 46% was the decline in payments to legitimate DME suppliers associated with competitive bidding in the United States, according to a 2026 study.[38]
- 35% was the reduction in total Medicare DME spending associated with competitive bidding in the United States, according to a 2026 study.[38]
- 23% was the decline in Medicare DME prices associated with competitive bidding in the United States, according to a 2026 study of the program.[38]
- 2,900 firms was the approximate number of fraudulent or suspicious DME suppliers identified in the study’s United States sample.[38]
Cost reduction in the dme industry
- 878.7% was the increase in AdaptHealth’s goodwill-impairment expense in 2025, reaching $128.0 million in the United States.[18]
- 3.5% was the increase in AdaptHealth’s rent and occupancy expense in 2025, reaching $74.391 million in the United States.[18]
- 0.5% was the increase in AdaptHealth’s cost of products and supplies in 2025, reaching $1.294 billion in the United States.[18]
- 65.5% was the decline in AdaptHealth’s operating income in 2025, falling to $90.9 million in the United States.[18]
- 3.7% was the increase in AdaptHealth’s other operating expenses in 2025, reaching $175.248 million in the United States.[18]
Profitability in the dme industry
- 50.2% was Rotech Healthcare’s gross margin in 2024, calculated from $364.661 million gross profit and $725.756 million revenue in the United States.[18]
- 2.2% was AdaptHealth’s net-loss margin attributable to the company in 2025 in the United States.[18]
- 22.5% was AdaptHealth Sleep Health’s adjusted EBITDA margin in 2025 in the United States.[18]
- 2.8% was AdaptHealth’s operating-income margin in 2025 in the United States.[18]
- 3.2% was AdaptHealth’s approximate gross margin in 2025, calculated from $3.245 billion revenue less $2.636 billion cost of net revenue in the United States.[18]
Financial planning in the dme industry
- 70.794 million dollars was AdaptHealth’s net loss attributable to the company in 2025 in the United States.[18]
- 1.086 billion dollars was AdaptHealth’s net revenue from fixed monthly equipment reimbursements in 2025 in the United States.[18]
- 105.753 million dollars was AdaptHealth’s net interest expense in 2025 in the United States.[18]
- 50.884 million dollars was AdaptHealth’s income-tax expense in 2025 in the United States.[18]
- 3.245 billion dollars was AdaptHealth’s net revenue in 2025 in the United States.[18]
12 Statistics
Product & Service
We separate product and regulatory signal flows using FDA clearance shares, including 20.0% digitally connected devices in 2025 and 3 years as the minimum expected operating life for DME under U.S. Medicare rules.
Product development in the dme industry
- 17.3% of classifiable U.S. FDA 510(k) clearances described digitally connected devices in 2024, indicating the share of connected product development entering the market.[12]
- 20.0% of classifiable U.S. FDA 510(k) clearances described digitally connected devices in 2025.[12]
- $266.50 billion was the global DME market value in 2025, supporting continued product-development investment across equipment categories worldwide.[39]
- 1,764 U.S. FDA 510(k) clearances were recorded in the connected-care dataset from January 1 through July 26, 2026.[12]
- 8.2% of classifiable U.S. FDA 510(k) clearances described cloud-connected devices in 2025.[12]
Product lifecycle in the dme industry
- 30–50% lower embodied emissions were reported for remanufactured medical systems compared with new systems in a 2025 DME market analysis.[40]
- 8 years was the expected service life of Inogen’s Rove 6 portable oxygen concentrator in the United States and Canada.[41]
- 3 years is the minimum expected operating life required for equipment to qualify as DME under U.S. Medicare rules.[14]
- 4 quarterly DMEPOS fee-schedule files were listed by CMS for the United States in 2026.[14]
- 34.9% of Inogen’s total revenue came from outside the United States in 2024, reflecting the geographic reach of its product lifecycle.[18]
After-sales in the dme industry
- 333 U.S.-based Inogen employees focused on selling products and providing service and support worldwide at December 31, 2024.[18]
- 5 calendar days is the CMS quality-standard deadline for notifying a prescriber when a DMEPOS supplier cannot provide prescribed equipment or services.[14]
- 23 Inogen employees and contractors in Europe provided sales and customer-support services at December 31, 2024.[18]
- 21,800 patients received ventilator treatment from Lincare in 2024.[18]
- 385,000 oxygen patients were served by Lincare in the United States in 2024.[18]
Value proposition in the dme industry
- 6.2% was the projected global DME market compound annual growth rate for 2026–2035.[39]
- $283.02 billion was the estimated global DME market value for 2026.[39]
- 48 states were covered by AdaptHealth’s healthcare-at-home network in 2026.[19]
- $70.66 billion was the estimated U.S. DME market size in 2025.[21]
- 4.8 million patients were served annually by AdaptHealth’s healthcare-at-home network in 2026.[19]
13 Statistics
Sustainability & Ethics
We track emissions contributions and bounds tied to the medical-technology value chain, including a 10–20% end-of-life share of value-chain emissions in 2026 and 15–25% of healthcare emissions attributed to the medical technology sector.
Sustainability in the dme industry
- 40% of near-term medical technology emissions-reduction potential is estimated to come from renewable energy, renewable heat and efficiency measures, in 2026.[42]
- 5% of global greenhouse-gas emissions come from healthcare, including medical technology, in 2026.[42]
- 10–20% of medical technology value-chain emissions occur at end of life, according to 2026 sector estimates.[42]
- 5–10% of medical technology companies’ total emissions are directly under company control, with the remainder occurring across the value chain, in 2026.[42]
- 15–25% of healthcare’s global greenhouse-gas emissions are attributed to the medical technology sector, equivalent to about 1% of global emissions, in 2026.[42]
ESG in the dme industry
- 13 of the 20 largest medical-device companies reported Scope 3 emissions estimates in 2022, according to OECD analysis.[43]
- 52% of surveyed medtech companies with at least one sustainability strategy had defined processes for reviewing due diligence in 2024.[44]
- 64% of surveyed medtech companies that had defined at least one sustainability strategy had appointed a responsible person in 2024.[44]
- 75% of the 20 largest medical-device companies also reported Scope 3 emissions targets in the OECD’s analysis, published in 2025.[43]
- 9 of the 20 largest medical-device companies reported Scope 3 emissions estimates in 2023, according to OECD analysis.[43]
Circular economy in the dme industry
- 37% of surveyed medtech companies with at least one sustainability strategy had assessed products for recyclability in 2024.[44]
- 41.4% of Dutch healthcare waste production is attributed to pharmaceuticals and medical devices, according to cited research.[42]
- 25–30% of medical technology’s estimated additional emissions-abatement potential faces economic or regulatory barriers, according to 2026 sector estimates.[42]
- 901 tonnes of recyclable materials were among the 4.8 million tonnes of waste generated annually by 1,893 German hospitals, according to cited sector research.[42]
- 25–30% of medical technology’s emissions could potentially be reduced through circular-economy measures in the long term, according to MedTech Europe.[42]
Carbon footprint in the dme industry
- 57.9 gigajoules of Scope 1 and 2 energy were used per million dollars of revenue by ResMed in 2023.[45]
- 28,658 tonnes of Scope 1 and 2 carbon-dioxide equivalent emissions were reported by ResMed globally in 2024.[45]
- 6.7 tonnes of Scope 1 and 2 carbon-dioxide equivalent emissions per million dollars of revenue were reported by ResMed in 2023.[45]
- 51.8 gigajoules of Scope 1 and 2 energy were used per million dollars of revenue by ResMed in 2024.[45]
- 43% of surveyed medtech companies with at least one sustainability strategy had created a carbon footprint in 2024.[44]
14 Statistics
Risk, Compliance & Legal
We emphasize compliance triggers for connected and digital devices, including 84% of healthcare organizations including cybersecurity requirements in vendor RFPs in 2026 and 35% requiring a software bill of materials.
Risk Management in the medical devices sector (sector benchmark)
- 70% of medical device companies used manual documentation and spreadsheets for risk management during the design process in 2023.[46]
- 35% of medical device professionals cited unclear ownership of risk across the product life cycle as a risk-management challenge in 2024.[47]
- More than 50% of medical device professionals said they could not document closed-loop traceability in 2024.[47]
- 34% of medical device professionals cited insufficient access to appropriate information during design and development as a risk-management challenge in 2024.[47]
- 33% of medical device company leaders felt very confident in the integrity of risk-analysis data in 2023.[46]
Cybersecurity in the medical devices sector (sector benchmark)
- 84% of healthcare organizations across the United States, United Kingdom and Germany included cybersecurity requirements in medical-device vendor RFPs in 2026.[48]
- 56% of healthcare organizations across the United States, United Kingdom and Germany rejected a medical device because of cybersecurity concerns in 2026.[48]
- 28% of healthcare organizations across the United States, United Kingdom and Germany operated medical devices past end-of-support in 2026.[48]
- 80% of facilities attacked across the United States, United Kingdom and Germany reported moderate or significant patient-care impact in 2026.[48]
- 35% of healthcare organizations across the United States, United Kingdom and Germany would not consider a medical device without a software bill of materials in 2026.[48]
Data Privacy in the medical devices sector (sector benchmark)
- 30% of respondents rated data security for wearable medical devices very important in 2023.[49]
- 86% of medical-device stakeholders considered data security for digital health technologies extremely important in a 2023 survey.[50]
- 64% of respondents rated data security for wearable medical devices extremely important in 2023.[49]
- 47% of medtech respondents identified data privacy and security as a key development challenge for their companies in 2024.[51]
Crisis Management in the medical devices sector (sector benchmark)
- 89% of pharma, life-sciences, medtech and health organizations had established a crisis-management organization in 2020.[52]
- 61% of pharma, life-sciences, medtech and health organizations had conducted exercises with their crisis-management team in 2020.[52]
- 90% of pharma, life-sciences, medtech and health organizations had formulated a business-continuity-management strategy in 2020.[52]
- 57% of pharma, life-sciences, medtech and health organizations had pandemic planning in place in 2020.[52]
15 Statistics
Globalization & Expansion
We track export and supply-chain reach, including durable medical devices at 71.1% of global medical-device export value in 2025 and DME jurisdiction A covering 7,325,744 fee-for-service Medicare beneficiaries.
Globalization in the dme industry
- 71.1% was the share of durable medical devices in global medical-device export value in 2025.[53]
- 13.3% was China’s share of global medical-device exports in 2025.[53]
- 2.2% was the 2025 year-over-year growth rate for global durable medical-device exports.[53]
- 14.9% was Germany’s share of global medical-device exports in 2025, with durable devices accounting for most of its exports.[53]
- 18.0% was the United States’ share of global medical-device imports in 2025, with durable devices comprising most imports.[53]
Supplier management in the dme industry
Distribution channels in the dme industry
- 250-plus locations supported Accendra Health’s national in-home medical-equipment distribution footprint in fiscal 2025.[18]
- Nearly 4,500 customer locations were served by InfuSystem across the United States and Canada in 2025.[18]
- Approximately 85% of the United States population was accessible to Accendra Health through commercial, Medicare and Medicaid payer relationships in fiscal 2025.[18]
- 20.9% was DME Jurisdiction A’s share of the national DME workload as of September 30, 2025.[14]
- 7,325,744 fee-for-service Medicare beneficiaries were covered in DME Jurisdiction A as of September 30, 2025.[14]
Key questions about the Dme Industry
What is the current global DME market size, and how fast is it expanding?
How does home care affect DME demand versus institutional care?
Which companies lead the dme industry?
What technology changes are most visible in connected DME and data workflows?
How concentrated or fragmented is the DME market structure?
What compliance and reimbursement pressures affect suppliers most directly?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Julian Richter. (2026, February 13). Dme Industry Statistics. Gitnux. https://gitnux.org/dme-industry-statistics
Julian Richter. "Dme Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/dme-industry-statistics.
Julian Richter. 2026. "Dme Industry Statistics." Gitnux. https://gitnux.org/dme-industry-statistics.
Sources & references
67 sources cited across this report
nsf.org
mastercontrol.com
bcg.com
monitor-industrial-ecosystems.ec.europa.eu
veeva.com
pages.awscloud.com
plm.automation.siemens.com
modeln.com
www-statista-com.libproxy.pcc.edu
ashb.com
eseye.com
starfishmedical.com
- hcahealthcareimpact.com
cms.gov
- sana-suisse-med.ch
blog.greenlight.guru
distillersr.com
sec.gov
- adapthealth.com
investor.resmed.com
grandviewresearch.com
- physiciangrowthpartners.com
- jahaniandassociates.com
earnings-documents-prod.s3.amazonaws.com
pmcf.com
dotmed.com
nychealthandhospitals.org
hcai.ca.gov
mddionline.com
cultureamp.com
- nphihealth.org
hme-business.com
media.sproutsocial.com
- brand-news.it
owens-minor.com
alirahealth.com
nber.org
gminsights.com
mordorintelligence.com
investor.inogen.com
medtecheurope.org
oecd.org
- rosapeak.com
cognition.us
runsafesecurity.com
dennemeyer.com
mdic.org
deloitte.com
- 2bridge.partners
krungsri.com
arxiv.org
fred.stlouisfed.org
medline.com
stryker.com
pridemobility.com
sunrisemedical.com
arjo.com
permobil.com
lincare.com
apria.com
aarp.org
who.int
fda.gov